BridgeBio Pharma (BBIO) Net Cash Flow (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 524.75% |
| Dec 31, 2025 | 31.18% |
| Sep 30, 2025 | -150.88% |
| Jun 30, 2025 | 248.30% |
| Mar 31, 2025 | -151.02% |
| Dec 31, 2024 | 294.42% |
| Sep 30, 2024 | -296.68% |
| Jun 30, 2024 | -12.99% |
| Mar 31, 2024 | 163.96% |
| Dec 31, 2023 | -164.87% |
| Sep 30, 2023 | 280.60% |
| Jun 30, 2023 | -706.12% |
| Mar 31, 2023 | 126.45% |
| Dec 31, 2022 | -624.40% |
| Sep 30, 2022 | -86.65% |
| Jun 30, 2022 | 544.04% |
| Mar 31, 2022 | -110.40% |
| Dec 31, 2021 | 207.69% |
| Sep 30, 2021 | -113.77% |
| Jun 30, 2021 | -180.50% |
| Mar 31, 2021 | 1,421.11% |
| Dec 31, 2020 | 94.99% |
| Sep 30, 2020 | 19.52% |
| Jun 30, 2020 | -154.96% |
| Mar 31, 2020 | 883.42% |
| Dec 31, 2019 | -141.77% |
| Sep 30, 2019 | 252.50% |
| Jun 30, 2019 | -24.65% |
| Mar 31, 2019 | -128.20% |
| Dec 31, 2018 | 651.39% |